CN106176292A - A kind of biodegradable injection molding process decorative material and preparation method thereof - Google Patents
A kind of biodegradable injection molding process decorative material and preparation method thereof Download PDFInfo
- Publication number
- CN106176292A CN106176292A CN201610563450.0A CN201610563450A CN106176292A CN 106176292 A CN106176292 A CN 106176292A CN 201610563450 A CN201610563450 A CN 201610563450A CN 106176292 A CN106176292 A CN 106176292A
- Authority
- CN
- China
- Prior art keywords
- plga
- hyaluronic acid
- molding process
- injection molding
- collagen protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 title claims abstract description 13
- 238000001746 injection moulding Methods 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 26
- 108010035532 Collagen Proteins 0.000 claims abstract description 23
- 102000008186 Collagen Human genes 0.000 claims abstract description 23
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940046009 vitamin E Drugs 0.000 claims abstract description 13
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 13
- 239000011709 vitamin E Substances 0.000 claims abstract description 13
- 239000004005 microsphere Substances 0.000 claims abstract description 11
- 230000001954 sterilising effect Effects 0.000 claims abstract description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 abstract description 24
- 239000007924 injection Substances 0.000 abstract description 24
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 19
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 19
- 208000005189 Embolism Diseases 0.000 abstract description 10
- 229920001436 collagen Polymers 0.000 abstract description 6
- 206010015150 Erythema Diseases 0.000 abstract description 5
- 208000001435 Thromboembolism Diseases 0.000 abstract description 5
- 230000003796 beauty Effects 0.000 abstract description 5
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 210000001927 retinal artery Anatomy 0.000 abstract description 4
- 206010003178 Arterial thrombosis Diseases 0.000 abstract description 3
- 208000000112 Myalgia Diseases 0.000 abstract description 3
- 208000003251 Pruritus Diseases 0.000 abstract description 3
- 208000024780 Urticaria Diseases 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 abstract description 3
- 230000004087 circulation Effects 0.000 abstract description 3
- 231100000429 cutaneous necrosis Toxicity 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 210000002216 heart Anatomy 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000003716 rejuvenation Effects 0.000 abstract description 3
- 238000007493 shaping process Methods 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 206010040954 Skin wrinkling Diseases 0.000 description 11
- 230000037303 wrinkles Effects 0.000 description 10
- 229920000954 Polyglycolide Polymers 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 208000031481 Pathologic Constriction Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000004626 polylactic acid Substances 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 229950008885 polyglycolic acid Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000011806 microball Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010008457 Artecoll Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 208000018999 crinkle Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to medical science shaping and beauty technical field, particularly to face filling and anti-wrinkle technical field, specifically, be that defying age, beautifying skin, face rejuvenation material are modified in a kind of injection molding process beauty treatment.Invention formulation formula includes hyaluronic acid, collagen protein, vitamin E and PLGA.Its preparation method includes: 1) prepare high-viscosity gel；2) PLGA Nano microsphere is prepared；3) high-viscosity gel and PLGA Nano microsphere are sufficiently mixed；4) sterilization fill.Compared with prior art, the invention have the advantages that: collagen protein is used in combination with hyaluronic acid, decrease skin erythema, swelling, hardening or pruritus, myalgia that single product collagen injections agent may cause, the symptom such as urticaria or other erythra.Reducing the blood vessel distal circulation thromboembolism that simple hyaluronic acid injections may cause, cutaneous necrosis, the generation of the severe complication probability such as embolism of retinal artery and heart and brain arterial thrombosis, product safety in utilization improves.
Description
Technical field:
The present invention relates to medical science shaping and beauty technical field, particularly to face filling and anti-wrinkle technical field, specifically
Ground is said, is that defying age, beautifying skin, face rejuvenation material are modified in a kind of injection molding process beauty treatment.
Background technology:
With advancing age, the skin degenerative change of people constantly aggravates, the minimizing of skin corium collagen content and
The water content of skin reduces, and is one of main cause of occurring of wrinkle, therefore, skin corium or subcutaneous direct injection collagen protein and guarantor
The hyaluronic acid that aqueous is stronger is considered to solve the effective ways of wrinkle problem.Progress and people's living standard along with society
Improving, people are increasing year by year for the demand of the medical bio injection material for face rejuvenation and defying age, defying age
The service organization of industry and beautifying medical industry is annual to be also incremented by according to times several levels.
Injectivity anti-wrinkle product in the market mainly has collagen injections filler, and (" double U.S. " such as Taiwan injects
Filler) and hyaluronic acid (hyaluronic acid) injection molding process agent (as Sweden auspicious orchid, France Evolution, Holland Artecoll
Deng), these several preparations there is also following defect to be needed to solve:
1, function singleness:
At present the most no matter collagen protein or hyaluronic acid filler, domestic and imported product is simple function preparation, only
Can play filling effect, the most different products maintains filling effect and timeliness to have nothing in common with each other, and does not has the merit of antioxidation, defying age
Energy.
2, complication is more serious:
Collagen protein will not can cause the rejection that body is serious as other exogenous implants, but injection molding process
The collagen sources of agent is in xenogeneic skin, and the protein of heterologous can cause allergic reaction in theory, such as local skin
Erythema, swelling, hardening and/or pruritus etc..Serious may occur in which General Symptoms such as fever, headache, myalgia, nauseating, whole body is weary
There is urticaria or other erythra, or various immune disease in power or dizziness, whole body.So collagen protein purely there may be
Acute and chronic anaphylaxis.
Single hyaluronic acid injection anti-wrinkle product is to make molecular weight add through method chemically or physically mostly
Greatly, after in injection process, hyaluronic acid once enters blood clinically, it is possible to causing blood vessel distal to circulate thromboembolism, skin is bad
Extremely, the severe complication such as embolism of retinal artery and heart and brain arterial thrombosis.Report of Complications got more and more in recent years, sent out every year
It is hundreds of that raw peripheral circulation thromboembolism causes cutaneous necrosis, and embolism of retinal artery causes permanent loss vision tens example, cerebral vessels embolism
Cause there is report during the severe complications such as the language dyskinesia, cerebral edema.Therefore existing like product both domestic and external all exists the biggest
Safety issue.
3, curative effect is held time comparatively short:
Owing to collagen protein and hyaluronan molecule amount are less so that they be injected into human body skin subcutaneous after,
Degraded i.e. can be completely absorbed in some months.The hyaluronic acid cross-linked without chemically or physically method or collagen material
Maintain the effect time comparatively short in vivo, only 3～about 4 months；Hyaluronic acid after crosslinked holds time the most only 6 in vivo
～about 8 months.Therefore curative effect is held time shorter.
Summary of the invention:
The problem to be solved in the present invention is aiming at above deficiency and provides a kind of and both had filling modification to skin,
Can play again defying age and whitening function, and the compound formulation that the curative effect injection filling of holding time longer is modified.Its technology
Scheme is as follows:
Invention formulation formula includes the component of following weight portion:
Its preparation method comprises the following steps:
1) take 10～35 parts of hyaluronic acids and 5～25 parts of collagen protein are prepared by mixing into high-viscosity gel；
2) take 0.2～0.5 part of vitamin E and 20～35 parts of PLGA are sufficiently mixed, make vitamin E be closed system by PLGA embedding
Become Nano microsphere；
3) high-viscosity gel and PLGA Nano microsphere are sufficiently mixed；
4) fill after sterilization.
Product of the present invention has the following characteristics that
1, outward appearance: product of the present invention is that semi-transparent clear acid freezes shape, naked eyes without any impurity and foreign body.
2, specification:
0.5ml standard loading amount 0.505 ± 0.002
1.0ml standard loading amount 1.050 ± 0.002
3, osmotic pressure:
280mosm/L～356mosm/L
Microsphere maximum grain < 200 μm
Swellbility < 20
Syringe pushes away material and squeezes power 30G syringe needle pushing force < 35N
4, biological property:
Bacteria containing amount: aseptic
Botulin A creotoxin: containing antibacterial creotoxin amount < 0.5BU/ml
Hemolytic streptococcus hemolysin: without zone of hemolysis
Cytotoxicity: be not more than first order reaction or nothing
Delayed hypersensitivity reaction: nothing
Skin irritation: nothing
Genetoxic: nothing
5, chemical property:
Acid-base value (pH) value 6.5～7.5
Content of beary metal < 5 μ g/g
Solvent residual amount < 2 μ g/g
Compared with prior art, the invention have the advantages that:
1, the consumption of product collagen protein of the present invention and hyaluronic acid is that collagen protein accounts for collagen protein and transparent respectively
The 1/3 of matter acid total amount, hyaluronic acid accounts for the connection of collagen protein and the 2/3 of hyaluronic acid total amount, collagen protein and hyaluronic acid
Close and use, decrease skin erythema, swelling, hardening or pruritus that single product collagen injections agent may cause, fever, head
Pain, myalgia, the symptom such as urticaria or other erythra, product the most of the present invention subtracts compared with the simple hyaluronic acid injections of prior art
Lack the consumption of the hyaluronic acid more than 30%, thus significantly reduce the blood vessel end that simple hyaluronic acid injections may cause
Tip circulation thromboembolism, cutaneous necrosis, the generation of the severe complication probability such as embolism of retinal artery and heart and brain arterial thrombosis.Product makes
It is greatly improved with safety.
2, vitamin E is embedded by product PLGA of the present invention as carrier: vitamin E as the most best antioxidation and
Oxygen free radical scavenger, makes Nano microsphere, at subcutaneous alleviation On The Drug Release after implantation, for delaying skin by it with PLGA embedding
Cell survival has obvious effect, in addition to having filling rhetorical function, also add scavenging activated oxygen function, it is possible to play antioxygen
Change the effect of anti aging effect.Therefore the present invention has filling and resisting age of skin double effects, and breakthrough innovation is regenerated, performance
Stable, secure persistent, has the anti-ageing dual-use function of U.S. face.With syringe subcutaneous injection to lax or the facial tissue of fold
In, reach the purpose of shaping and beauty.
3, product of the present invention is used as the PLGA of carrier, by two kinds of monomers--polylactic acid (poly lactide,
Polylacticacid, PLA) and polyglycolic acid (polyglycolide, polyglycolicacid, PGA) be polymerized, can
It is referred to as poly (lactic acid-glycolic acid) (PLGA).This polymer is made up of 70%～75% polylactic acid and 25%～30% polyglycolic acid, can
Slowly degrade with control PLGA, there is the longer half-life, retention time controllable in health, its curative effect retention time is long,
Effective time can maintain 18～24 months.Overcome short defect of simple Injection of Hyaluronic Acid gel retention time, can reach
The purpose of product of the present invention release therapeutic dose the most stable, slow, effective.
4, PLGA is a kind of degradable macromolecular organic compound, and its catabolite is polylactic acid and polyglycolic acid, with
Time be also the by-product of body metabolism approach, there is good biocompatibility, be widely used in pharmacy, medical engineering material
Field, does not has toxic and side effects.So product of the present invention does not only have rejection, during injection, do not have red and swollen phenomenon etc. bad instead yet
Should.It is applicable to drainer for plastic surgery Soft-tissue operation, such as face crinkle-removing, depression filling etc., volume band, crows-feet, eyebrow can be eliminated
Interband, muffle stricture of vagina, perioral aging lines and cicatrix.
5, the present invention uses nanometer microsphere preparation technology, antigenicity to significantly reduce and degraded and absorbed is few, its main component glue
Former albumen and hyaluronan molecule amount are less, can enter renal excretion by microcirculation and go out external after entering blood, Bu Huizao
Become blood vessel distal circulation thromboembolism, complication can be reduced, avoid the generation of severe complication.
In order to verify the safety of product of the present invention, applicant has made following clinical experiment and has been checked:
One, experimenter: 40:
1, one full year of life at age 30～65, healthy person without Other diseases, male or female；
2, eliminate or alleviate the experimenter of face wrinkle and depression voluntarily；
3, facial area is with the presence of obvious macroscopic decree stricture of vagina, the glabella stricture of vagina of static state, forehead stricture of vagina, eye rill, fish tail
Stricture of vagina, and lower eyelid depression and other Facial Depression or face have chloasma person etc..
Two, test period: 3 months
Three, test method:
1, medicine:
Product of the present invention, by the trial-production of Jiangsu Hua Yimei element bioengineered tissue company limited, specification: 1ml/ props up.Preserve bar
Part: 2-8 degree Celsius, effect duration: 2 years.
2, test procedure:
(1) blood drawing, checks liver function and kidney merit；
(2) screening: clinician reviews draws blood report, eligible entrance next step；
(3) foundation facilitates the principle of experimenter, and 40 experimenters are divided into 3 groups, notes three different time periods respectively
Penetrate；
(4) administrated method: first accept skin allergy test before injection, observe a week, can carry out without anaphylaxis person；
(5) inject front preform injection site assessments and take pictures, when taking pictures, put scale record；
(6) injection: take out the product of the present invention being saved in refrigerator, wait to rise again to room temperature state, with 30G needle injection,
Depending on injection depth and dosage are because of position and the order of severity；
(7) injection was observed after 48 hours, with or without redness, ecchymosis etc., took pictures and record in main detection local；
(8) injection was observed after 7 days, and redness, ecchymosis and the preliminary efficacy of main detection local is taken pictures and record；
(9) injection was observed after 1 month, and main detection curative effect and have the performance having no adverse reaction is taken pictures and record；
(10) person inconspicuous for curative effect supplements injection, and injecting method is the same；
(11) injection was observed after 3 months, and main detection curative effect and have the performance having no adverse reaction is taken pictures and record；
(12) data statistics analyse, carries out efficacy determination according to curative effect determinate standard；
(13) test report.
Four, clinical evaluation standard:
1, excellent: wrinkle or depression are wholly absent, reach to fill and lead up effect or pigmented spots alleviate；
2, good: wrinkle or depression are improved substantially, reach satisfied effect of filling and leading up, but wrinkle or depression naked eyes still can be seen；
3, in: wrinkle or depression have a certain degree of improvement, but improve dissatisfied, and wrinkle or depression are the most more apparent；
4, poor: without improving before the relatively injection of wrinkle or depression, wrinkle or depression are the most high-visible
Five, conclusion:
Through above-mentioned test and evaluation statistics, 40 people there are 30 people be evaluated as excellent, accounting 75%；8 people are had to be evaluated as
Good, accounting 20%；In having 1 people to be evaluated as, accounting 2.5%；1 people is had to be evaluated as poor, accounting 2.5%.This product of empirical tests
Harmless to human non-toxic, total effective rate reaches 97.5%.
Detailed description of the invention:
Embodiment one:
A kind of biodegradable injection molding process decorative material, including the component of following weight portion:
Its preparation method comprises the following steps:
1) take 10 parts of hyaluronic acids and 25 parts of collagen protein are prepared by mixing into high-viscosity gel；
2) take 0.2 part of vitamin E and 35 parts of PLGA are sufficiently mixed, make vitamin E be made nanometer by PLGA embedding closing micro-
Ball；
3) by step 1) prepare high-viscosity gel and step 2) prepare PLGA Nano microsphere be sufficiently mixed；
4) fill after sterilization.
Embodiment two:
A kind of biodegradable injection molding process decorative material, including the component of following weight portion:
Its preparation method comprises the following steps:
1) take 35 parts of hyaluronic acids and 5 parts of collagen protein are prepared by mixing into high-viscosity gel；
2) take 0.5 part of vitamin E and 20 parts of PLGA are sufficiently mixed, make vitamin E be made nanometer by PLGA embedding closing micro-
Ball；
3) by step 1) prepare high-viscosity gel and step 2) prepare PLGA Nano microsphere be sufficiently mixed；
4) fill after sterilization.
Embodiment three:
A kind of biodegradable injection molding process decorative material, including the component of following weight portion:
Its preparation method comprises the following steps:
1) take 20 parts of hyaluronic acids and 10 parts of collagen protein are prepared by mixing into high-viscosity gel；
2) take 0.25 part of vitamin E and 30 parts of PLGA are sufficiently mixed, make vitamin E be made nanometer by PLGA embedding closing micro-
Ball；
3) by step 1) prepare high-viscosity gel and step 2) prepare PLGA Nano microsphere be sufficiently mixed；
4) fill after sterilization.
Claims (2)
1. a biodegradable injection molding process decorative material, it is characterised in that include the component of following weight portion:
2. the preparation method of a biodegradable injection molding process decorative material, it is characterised in that comprise the following steps:
1) take 10～35 parts of hyaluronic acids and 5～25 parts of collagen protein are prepared by mixing into high-viscosity gel；
2) take 0.2～0.5 part of vitamin E and 20～35 parts of PLGA are sufficiently mixed, make vitamin E be made by PLGA embedding closing and receive
Meter Wei Qiu；
3) high-viscosity gel and PLGA Nano microsphere are sufficiently mixed；
4) fill after sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610563450.0A CN106176292A (en) | 2016-07-16 | 2016-07-16 | A kind of biodegradable injection molding process decorative material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610563450.0A CN106176292A (en) | 2016-07-16 | 2016-07-16 | A kind of biodegradable injection molding process decorative material and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106176292A true CN106176292A (en) | 2016-12-07 |
Family
ID=57475960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610563450.0A Pending CN106176292A (en) | 2016-07-16 | 2016-07-16 | A kind of biodegradable injection molding process decorative material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176292A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727244A (en) * | 2017-01-10 | 2017-05-31 | 成都中科同体生物医学研究院 | Consubstantiality biological microsphere and the syringe for injecting the microballoon |
| CN110327488A (en) * | 2019-07-18 | 2019-10-15 | 王月玲 | A kind of injection fillers microball preparation and preparation method thereof |
| CN110404109A (en) * | 2019-08-15 | 2019-11-05 | 深圳兰度生物材料有限公司 | Soft tissue filler and preparation method thereof |
| CN110787319A (en) * | 2019-11-19 | 2020-02-14 | 上海摩漾生物科技有限公司 | Implant for facial cosmetic lifting and application thereof |
| CN111419780A (en) * | 2020-05-07 | 2020-07-17 | 南京恒奥源医疗器械有限公司 | Facial composition and application thereof |
| CN111544656A (en) * | 2020-06-16 | 2020-08-18 | 深圳兰度生物材料有限公司 | Dermal filler and preparation method thereof |
| CN113081896A (en) * | 2021-05-10 | 2021-07-09 | 拉菲尔(深圳)投资咨询有限公司 | Regenerative medical injection for facial rejuvenation and application thereof |
| CN113117143A (en) * | 2020-01-14 | 2021-07-16 | 北京四环制药有限公司 | Application of hyaluronic acid in preparing composition for reducing injection irritation of PLLA |
| CN113144288A (en) * | 2021-04-26 | 2021-07-23 | 磐升瑞祥(山东)生物工程有限公司 | Composite multi-component collagen micro-emulsion filler and preparation method thereof |
| CN113244457A (en) * | 2018-05-21 | 2021-08-13 | 白晋 | Injection composition applied to beauty filling |
| CN113244134A (en) * | 2021-05-07 | 2021-08-13 | 南京中源盛生物科技研究院有限公司 | Skin care product active substance micro/nano sphere-hydrogel and preparation method thereof |
| CN113877000A (en) * | 2021-10-13 | 2022-01-04 | 科笛生物医药(无锡)有限公司 | Microsphere composition for injection and application thereof |
| CN114176698A (en) * | 2021-12-20 | 2022-03-15 | 神遁医疗科技(上海)有限公司 | Embolism object |
| CN114931666A (en) * | 2022-06-09 | 2022-08-23 | 海雅美生物技术(珠海)有限公司 | Preparation method of hyaluronic acid-collagen composite cross-linked microspheres for facial filling |
| CN115501389A (en) * | 2022-09-16 | 2022-12-23 | 上海市第五人民医院 | A filling composition for skin and surrounding tissue |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007062113B4 (en) * | 2007-12-21 | 2011-05-12 | Bettina Lingenfelder | Dermatological preparation |
| CN103333349A (en) * | 2013-06-28 | 2013-10-02 | 陕西巨子生物技术有限公司 | Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof |
| CN103357066A (en) * | 2013-06-28 | 2013-10-23 | 陕西巨子生物技术有限公司 | Hydrogel with bioremediation activity and outstanding degradation performance and preparation method |
| CN104667346A (en) * | 2015-03-21 | 2015-06-03 | 杨青芳 | Preparation method of biodegradable nano-microsphere and application |
-
2016
- 2016-07-16 CN CN201610563450.0A patent/CN106176292A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007062113B4 (en) * | 2007-12-21 | 2011-05-12 | Bettina Lingenfelder | Dermatological preparation |
| CN103333349A (en) * | 2013-06-28 | 2013-10-02 | 陕西巨子生物技术有限公司 | Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof |
| CN103357066A (en) * | 2013-06-28 | 2013-10-23 | 陕西巨子生物技术有限公司 | Hydrogel with bioremediation activity and outstanding degradation performance and preparation method |
| CN104667346A (en) * | 2015-03-21 | 2015-06-03 | 杨青芳 | Preparation method of biodegradable nano-microsphere and application |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727244A (en) * | 2017-01-10 | 2017-05-31 | 成都中科同体生物医学研究院 | Consubstantiality biological microsphere and the syringe for injecting the microballoon |
| CN113244457A (en) * | 2018-05-21 | 2021-08-13 | 白晋 | Injection composition applied to beauty filling |
| CN110327488B (en) * | 2019-07-18 | 2021-10-22 | 王月玲 | Injection filling microsphere preparation and preparation method thereof |
| CN110327488A (en) * | 2019-07-18 | 2019-10-15 | 王月玲 | A kind of injection fillers microball preparation and preparation method thereof |
| CN110404109A (en) * | 2019-08-15 | 2019-11-05 | 深圳兰度生物材料有限公司 | Soft tissue filler and preparation method thereof |
| CN110787319A (en) * | 2019-11-19 | 2020-02-14 | 上海摩漾生物科技有限公司 | Implant for facial cosmetic lifting and application thereof |
| CN113117143B (en) * | 2020-01-14 | 2023-11-28 | 渼颜空间(河北)生物科技有限公司 | Use of hyaluronic acid for producing biodegradable polymer microparticle formulations |
| CN113117143A (en) * | 2020-01-14 | 2021-07-16 | 北京四环制药有限公司 | Application of hyaluronic acid in preparing composition for reducing injection irritation of PLLA |
| CN111419780A (en) * | 2020-05-07 | 2020-07-17 | 南京恒奥源医疗器械有限公司 | Facial composition and application thereof |
| CN111544656A (en) * | 2020-06-16 | 2020-08-18 | 深圳兰度生物材料有限公司 | Dermal filler and preparation method thereof |
| CN113144288A (en) * | 2021-04-26 | 2021-07-23 | 磐升瑞祥(山东)生物工程有限公司 | Composite multi-component collagen micro-emulsion filler and preparation method thereof |
| CN113244134A (en) * | 2021-05-07 | 2021-08-13 | 南京中源盛生物科技研究院有限公司 | Skin care product active substance micro/nano sphere-hydrogel and preparation method thereof |
| CN113081896A (en) * | 2021-05-10 | 2021-07-09 | 拉菲尔(深圳)投资咨询有限公司 | Regenerative medical injection for facial rejuvenation and application thereof |
| CN113877000A (en) * | 2021-10-13 | 2022-01-04 | 科笛生物医药(无锡)有限公司 | Microsphere composition for injection and application thereof |
| CN113877000B (en) * | 2021-10-13 | 2023-01-24 | 科笛生物医药(无锡)有限公司 | Microsphere composition for injection and application thereof |
| CN114176698A (en) * | 2021-12-20 | 2022-03-15 | 神遁医疗科技(上海)有限公司 | Embolism object |
| CN114176698B (en) * | 2021-12-20 | 2024-04-26 | 神遁医疗科技(上海)有限公司 | Embolic material |
| CN114931666A (en) * | 2022-06-09 | 2022-08-23 | 海雅美生物技术(珠海)有限公司 | Preparation method of hyaluronic acid-collagen composite cross-linked microspheres for facial filling |
| CN115501389A (en) * | 2022-09-16 | 2022-12-23 | 上海市第五人民医院 | A filling composition for skin and surrounding tissue |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106176292A (en) | A kind of biodegradable injection molding process decorative material and preparation method thereof | |
| CN104395348B (en) | The method for preparing the composition based on hyaluronic acid | |
| Haneke | Adverse effects of fillers and their histopathology | |
| CN107213028A (en) | A kind of collagen implant and preparation method thereof | |
| RU2006139141A (en) | METHOD FOR INCREASING THE VOLUME OF SOFT TISSUES | |
| JP2007532173A5 (en) | ||
| KR20200143407A (en) | Neurotoxin for use in inhibiting CGRP | |
| BR112015031026B1 (en) | method for crosslinking hyaluronic acid or one of its salts or other biocompatible polymers; method for preparing an injectable hydrogel; hydrogel; kit and use | |
| JP2013500315A (en) | Injectable composition combining filler and fibroblast growth medium | |
| CN111110623A (en) | Self-repairing small needle nutrient solution formula | |
| CN102781463A (en) | Methods and compositions for skin regeneration | |
| CN102247618A (en) | Dermal filler composition | |
| CN110279888A (en) | A kind of injection Ago-Gel agent and preparation method thereof | |
| BR112019019743A2 (en) | botulinum neurotoxins for use in therapy | |
| US20210369612A1 (en) | Slurry and solution compositions | |
| Kim et al. | A randomized, evaluator-blinded, split-face comparison study of the efficacy and safety of a novel mannitol containing monophasic hyaluronic acid dermal filler for the treatment of moderate to severe nasolabial folds | |
| US20090023631A1 (en) | Composition and Method of Use for Soft Tissue Augmentation/Drug Delivery | |
| CN110279887A (en) | A kind of multipurpose photon epoxy resin and preparation method thereof | |
| BR112020012466A2 (en) | neurotoxins for use in minimizing scarring | |
| Douglas et al. | Collagen fillers in facial aesthetic surgery | |
| US20220257494A1 (en) | Methods and compositions for microflillng the skin with hyaluronic acid using microchannel technology | |
| CN102458421A (en) | Pharmaceutical agents | |
| Scarano et al. | Full-facial rejuvenation with autologous platelet-derived growth factors | |
| KR20160072627A (en) | filler composition | |
| Velthuis et al. | Fillers and Vessels: The Story of Arterial Obstruction after Cosmetic Treatment. J Angiol Vasc Surg 6: 069 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161207 |
|
| RJ01 | Rejection of invention patent application after publication |